Camblong Jurgi sold $209K of SOPH
Camblong Jurgi (Executive Chairman) sold 28,500 shares of SOPHiA GENETICS SA (SOPH) at an average of $7.34 ($7.23–$7.61, $0.21M total) across 2 trades over 2026-08-07 to 2026-08-10 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
Traders may briefly monitor for follow-on insider activity, but the 10b5-1 pre-arranged nature generally limits interpretive value.
Market read
A routine 10b5-1 insider sale for about $209K is unlikely to drive a sustained repricing without additional company-specific catalysts.
What to watch
The filing does not disclose reasons for the sale, and the weighted-average price range ($7.2270 to $7.6081) may reflect normal execution timing rather than a view on valuation.
Background
This is an SEC Form 4 insider transaction for SOPHiA GENETICS, reported by executive chairman Camblong Jurgi.
Ticker impact
SEC Form 4 shows SOPHiA GENETICS executive chairman Camblong Jurgi sold 28,500 shares for about $209K across two trades.
Likely minimal, unless traders interpret the sale as a sentiment read-through despite the 10b5-1 structure.
Form 4 details an open-market sale and explicitly notes a pre-arranged 10b5-1 plan, which typically reduces the informational content versus discretionary selling.
Market effects
No clear sector read-through from a single, small-to-moderate insider sale with 10b5-1 context.
None indicated.
None indicated.
Counterpoint
The sale could be purely liquidity-driven under the 10b5-1 plan and should not be treated as a bearish fundamental signal.
Key entities
- issuerSOPHiA GENETICS SA
Subject of the Form 4 insider transaction; executive chairman sold shares under a 10b5-1 plan.
- insiderCamblong Jurgi
Executive Chairman and reporting person who executed the open-market sale.
